Trials / Recruiting
RecruitingNCT05540262
Edaravone in the Treatment of Optic Neuritis
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- First Affiliated Hospital of Guangxi Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Edaravone | Edaravone injection 30mg three times a day |
Timeline
- Start date
- 2022-01-15
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2022-09-14
- Last updated
- 2025-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05540262. Inclusion in this directory is not an endorsement.